INQOVI (decitabine/cedazuridine)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for INQOVI (decitabine/cedazuridine), covering 2025-11-10 to 2026-04-17. Get the full timeline:
Most recent: Clinical Trial Update: Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma [Phase 2]